Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer

Adv Dent Res. 1998 Nov;12(2):97-102. doi: 10.1177/08959374980120012901.
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Apoptosis / drug effects
  • Cell Division / drug effects
  • Doxycycline / pharmacology
  • Doxycycline / therapeutic use
  • Drug Interactions
  • Epithelial Cells / drug effects
  • Flurbiprofen / pharmacology
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / secondary*
  • Male
  • Metalloendopeptidases / antagonists & inhibitors
  • Neoplasm Metastasis
  • Prostatic Neoplasms / enzymology
  • Prostatic Neoplasms / pathology*
  • Protease Inhibitors / pharmacology*
  • Rats
  • Regression Analysis
  • Tetracyclines / chemistry
  • Tetracyclines / pharmacology*
  • Tetracyclines / therapeutic use*
  • Tumor Cells, Cultured / drug effects

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Protease Inhibitors
  • Tetracyclines
  • tetracycline CMT-3
  • Flurbiprofen
  • Metalloendopeptidases
  • Doxycycline